Search details
1.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
N Engl J Med
; 388(10): 898-912, 2023 Mar 09.
Article
in English
| MEDLINE | ID: mdl-36884323
2.
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
Cancer
; 2024 May 04.
Article
in English
| MEDLINE | ID: mdl-38703010
3.
Disparate Outcomes, Biologic and Therapeutic Differences in Pediatric versus Adult Patients with Ewing Sarcoma.
Oncology
; 102(1): 1-8, 2024.
Article
in English
| MEDLINE | ID: mdl-37598679
4.
Body image disturbances in adolescent and young adult cancer patients confronting infertility risk and fertility preservation decisions.
J Psychosoc Oncol
; 42(2): 208-222, 2024.
Article
in English
| MEDLINE | ID: mdl-37452662
5.
Differentiating gender-based reproductive concerns among adolescent and young adult cancer patients: A mixed methods study.
J Psychosoc Oncol
; : 1-17, 2024 Jan 02.
Article
in English
| MEDLINE | ID: mdl-38164962
6.
Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board.
Cancer
; 129(21): 3363-3371, 2023 Nov 01.
Article
in English
| MEDLINE | ID: mdl-37403815
7.
Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.
Oncologist
; 28(5): 453-459, 2023 05 08.
Article
in English
| MEDLINE | ID: mdl-36724001
8.
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(8): 851-880, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37549914
9.
Integrative clinical genomics of metastatic cancer.
Nature
; 548(7667): 297-303, 2017 08 17.
Article
in English
| MEDLINE | ID: mdl-28783718
10.
Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications.
Oncologist
; 27(7): 595-599, 2022 07 05.
Article
in English
| MEDLINE | ID: mdl-35589095
11.
Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomas.
J Surg Oncol
; 125(8): 1292-1300, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35239187
12.
Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204.
Support Care Cancer
; 31(1): 93, 2022 Dec 31.
Article
in English
| MEDLINE | ID: mdl-36585488
13.
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Cancer
; 127(8): 1311-1317, 2021 04 15.
Article
in English
| MEDLINE | ID: mdl-33296083
14.
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Cancer
; 127(8): 1301-1310, 2021 04 15.
Article
in English
| MEDLINE | ID: mdl-33289920
15.
First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.
Lancet
; 395(10230): 1137-1144, 2020 04 04.
Article
in English
| MEDLINE | ID: mdl-32178768
16.
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Lancet Oncol
; 21(11): 1423-1432, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33035459
17.
Asymptomatic SARS-CoV-2 Infection and COVID-19 Mortality During an Outbreak Investigation in a Skilled Nursing Facility.
Clin Infect Dis
; 71(11): 2920-2926, 2020 12 31.
Article
in English
| MEDLINE | ID: mdl-32548628
18.
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
Invest New Drugs
; 38(5): 1421-1429, 2020 10.
Article
in English
| MEDLINE | ID: mdl-31984451
19.
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Cancer
; 125(14): 2445-2454, 2019 07 15.
Article
in English
| MEDLINE | ID: mdl-31034598
20.
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Invest New Drugs
; 37(3): 461-472, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30229512